Tous Actualités
Suivre
Abonner Antisoma plc

Antisoma plc

Antisoma to de-list from Nasdaq Europe because of forthcoming closure of market Shares to remain listed on the London Stock Exchange

London, UK (ots)

Antisoma  (LSE: ASM- Nasdaq Europe: ASOM), the
UK-based biopharmaceutical company, today announces that it has
received approval for a voluntary de-listing from the Nasdaq Europe
Market. The de-listing of Antisoma shares will be effective from the
close of business on Wednesday 10 September 2003. The decision to
de-list follows the announcement by Nasdaq Europe of its intention to
close by the end of November 2003.
Following the de-listing, all Antisoma shares will continue to be
traded on the London Stock Exchange, where the majority of trading
takes place at present. Existing shareholders will not have to take
any action to transfer their shareholdings. Importantly, they will
not incur any additional costs as a result of the de-listing.
Antisoma will continue to provide its shareholders with press
releases and related company information on www.antisoma.com.
About Antisoma
Based in London, UK, Antisoma is a biopharmaceutical company that
develops novel products for the treatment of cancer. The Company
fills its development pipeline by acquiring promising new product
candidates from internationally recognised academic or cancer
research institutions.  Its core activity is the pre-clinical and
clinical development of these drug candidates. Antisoma forms
partnerships with pharmaceutical companies to bring its products to
market. In November 2002, Antisoma signed a ground-breaking
collaboration agreement with Roche to develop and commercialise
products from Antisoma's pipeline.
This information is provided by RNS
       The company news service from the London Stock Exchange

Contact:

Antisoma plc
Raymond Spencer, Chief Financial Officer
Tel: +44/20/8799-8200

Financial Dynamics
Jonathan Birt
Tel: +44/7884-238952

Plus de actualités: Antisoma plc
Plus de actualités: Antisoma plc
  • 22.08.2003 – 08:17

    Results Presented From As1403 Phase I Biodistribution Study

    London, UK plc (LSE:ASM, NASD-E:ASOM) (ots) - Antisoma announces that results from its phase I biodistribution study of AS1403 (formerly TheraFab) will be presented this weekend to the European Association of Nuclear Medicine meeting in Amsterdam by Dr Michael Garkavij, a leading investigator in the trial. AS1403 is a fragment of the monoclonal antibody HMFG1 linked to a radioactive isotope with cell-killing ...